
|Videos|November 23, 2021
Dr. Bander on PSMA breakthroughs in prostate cancer
Author(s)Urology Times staff
“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.
Advertisement
Video Player is loading.
In this video, Neil H. Bander, MD, discusses PSMA therapeutic innovations for patients with prostate cancer and how they will change diagnosis and treatment. Bander is the Bernard & Josephine Chaus professor of urologic oncology at Weill Cornell Medicine, New York City, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
Andrea B. Apolo, MD, discusses survival gains with EV/pembrolizumab in bladder cancer
3
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
4
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
5